Author:
Ganesan Vishnuvardhan,Agarwal Deepak
Publisher
Springer Science and Business Media LLC
Reference49 articles.
1. Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urol Clin North Am. 2016;43:289–97.
2. Welliver C, Feinstein L, Ward JB, Fwu C-W, Kirkali Z, Bavendam T, et al. Trends in lower urinary tract symptoms associated with benign prostatic hyperplasia, 2004 to 2013: the Urologic Diseases in America Project. J Urol. 2020;203:171–8.
3. Caine M, Pfau A, Perlberg S. The use of alpha-adrenergic blockers in benign prostatic obstruction. Br J Urol. 1976;48:255–63.
4. Lepor H. Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol. 2007;9:181–90.
5. Yuan J-Q, Mao C, Wong SY-S, Yang Z-Y, Fu X-H, Dai X-Y, et al. Comparative effectiveness and safety of monodrug therapies for lower urinary tract symptoms associated with benign prostatic hyperplasia: a network meta-analysis. Medicine (Baltimore). 2015;94:e974.